Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD12 in Advanced Hodgkin Lymphoma
NCT00265031Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Jan 1999
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, doxorubicin, etoposide, procarbazine, prednisone and 2 more in Hodgkin lymphoma (HL) (4 arms), sponsored by University of Cologne. Primary endpoint: Freedom from Treatment Failure at 5 years. Started Jan 1999; status: completed.
02
Drugs
cyclophosphamidedoxorubicinetoposideprocarbazineprednisone
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00265031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265031.